Trial · NCT04738487
Outcomes50
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 50
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Survival (OS) in Participants With PD-L1 TPS ≥50% | Up to ~39 months | The analysis population consisted of all participants with PD-L1 TPS ≥ 50% who were randomized prior to the primary completion data cut-off. | Months | MEDIAN |
| SECONDARY | OS in Participants With PD-L1 TPS ≥1% | Up to ~39 months | The analysis population consisted of all participants with PD-L1 TPS ≥ 1% who were randomized prior to the primary completion data cut-off. | Months | MEDIAN |
| SECONDARY | OS in Participants With PD-L1 TPS 1% to 49% | Up to ~39 months | The analysis population consisted of all participants with PD-L1 TPS 1% to 49% who were randomized prior to the primary completion data cut-off. | Months | MEDIAN |
| SECONDARY | Progression-Free Survival (PFS) in Participants With PD-L1 TPS ≥1% | Up to ~56 months | |||
| SECONDARY | PFS in Participants With PD-L1 TPS ≥50% | Up to ~56 months | |||
| SECONDARY | PFS in Participants With PD-L1 TPS 1% to 49% | Up to ~56 months | |||
| SECONDARY | Objective Response Rate (ORR) in Participants With PD-L1 TPS ≥1% | Up to ~56 months | |||
| SECONDARY | ORR in Participants With PD-L1 TPS ≥50% | Up to ~56 months | |||
| SECONDARY | ORR in Participants With PD-L1 TPS 1% to 49% | Up to ~56 months | |||
| SECONDARY | Duration of Response (DOR) in Participants With PD-L1 TPS ≥50% | Up to ~56 months | |||
| SECONDARY | DOR in Participants With PD-L1 TPS 1% to 49% | Up to ~56 months | |||
| SECONDARY | DOR in Participants With PD-L1 TPS ≥1% | Up to ~56 months | |||
| SECONDARY | Change From Baseline in Global Health Status/Quality of Life (QoL) (Items 29, 30) Combined Score on the European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30) in Participants With PD-L1 TPS ≥50% | Baseline and up to ~56 months | |||
| SECONDARY | Change From Baseline in Global Health Status/QoL (Items 29, 30) Combined Score on the EORTC QLQ-C30 in Participants With PD-L1 TPS 1% to 49% | Baseline and up to ~56 months | |||
| SECONDARY | Change From Baseline in Global Health Status/QoL (Items 29, 30) Combined Score on the EORTC QLQ-C30 in Participants With PD-L1 TPS ≥1% | Baseline and up to ~56 months | |||
| SECONDARY | Change From Baseline in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 in Participants With PD-L1 TPS ≥50% | Baseline and up to ~56 months | |||
| SECONDARY | Change From Baseline in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 in Participants With PD-L1 TPS 1% to 49% | Baseline and up to ~56 months | |||
| SECONDARY | Change From Baseline in Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 in Participants With PD-L1 TPS ≥1% | Baseline and up to ~56 months | |||
| SECONDARY | Change From Baseline in Role Functioning (Items 6, 7) Combined Score on the EORTC QLQ-C30 in Participants With PD-L1 TPS ≥50% | Baseline and up to ~56 months | |||
| SECONDARY | Change From Baseline in Role Functioning (Items 6, 7) Combined Score on the EORTC QLQ-C30 in Participants With PD-L1 TPS 1% to 49% | Baseline and up to ~56 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04738487/outcomes